Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...

New blood test could show if prostate cancer treatment is failing - The discovery could lead to personalised treatments for the disease ...

The Alliance for Clinical Trials in Oncology has launched the ASPIRE trial-a large-scale, Phase III clinical study investigating whether adding chemotherapy to current standard treatments can extend ...

Technologies combining MRI, robotics, and artificial intelligence are changing the way prostate cancer is diagnosed and ...

A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with specific genetic mutations, finds a major international trial led by UCL ...

Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly. Diagnosis involves the TNM system, Gleason score, PSA tests, and imaging to ...

There are around 46,000 new cases of prostate cancer each year in England and Wales, with 13% of these cases showing signs of ...

Advanced screenings and longevity assessments are gaining traction in preventive health. But the value is more nuanced, according to Mayo Clinic’s Dr. Liz Gilman. In this Q&A, she shares where these ...

Prostate cancer diagnoses have been rising in recent years, with a sharp increase in cases diagnosed at advanced stages, when it is harder to treat, according to a new report by the American Cancer ...

Top urologists debunk prostate cancer myths, explain PSA testing, screening guidelines, risk factors, symptoms, and the ...

A new drug combo is offering hope for men with advanced prostate cancer. Adding the targeted cancer drug niraparib to hormone therapy reduced the risk of prostate tumor growth and slowed symptom ...

In a population-based study, patients with lower urinary tract symptoms (LUTS) or urinary tract infections (UTIs) were more than fourfold more likely to undergo prostate biopsy but showed 44% lower ...